osimertinib improves survival in egfr nsclc, poses new challenges for resistance
Published 4 years ago • 589 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
2:02
understanding egfr resistance in patients with met-amplified nsclc
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
1:02
osimertinib for treatment of egfr lung cancer
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
2:43
post-osimertinib treatment options for egfr nsclc - targeted therapies in lung cancer 2023
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
20:18
understanding, preventing, and delaying egfr resistance in the era of osimertinib
-
1:26
the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
4:38
new agents for egfr nsclc: osimertinib and beyond
-
5:52
treatment of egfr nsclc after osimertinib
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
3:09
case 2: osimertinib in egfr-mutated lung cancer